Story · Medicine & Biotech
Celltrion's Steqeyma wins EU panel backing for broader pediatric use
1 outlet · first reported by Korea Biomedical Review on
Celltrion said Monday that a European regulatory panel has recommended expanding the approved uses of its Stelara biosimilar Steqeyma (ustekinumab) to treat Crohn's disease and ulcerative colitis in children aged two and older.The European Medicines Agency's Committee for Medicinal Products for Huma (Korea Biomedical Review)
Coverage, in order
-
Celltrion's Steqeyma wins EU panel backing for broader pediatric use
Celltrion said Monday that a European regulatory panel has recommended expanding the approved uses of its Stelara biosimilar Steqeyma (ustekinumab) to treat Crohn's disease and ulcerative colitis in children aged two and older.The European Medicines Agency's Committee for Medicinal Products for Huma
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.